Nanotech report
This article was originally published in The Tan Sheet
Executive Summary
A new report commissioned by the Project on Emerging Nanotechnologies at the Woodrow Wilson International Center for Scholars stresses the need for regulatory oversight of nanotechnology and provides a "roadmap" for the Environmental Protection Agency to handle the challenges of the science, study author J. Clarence Davies claims. The report presents an agenda to create an "effective oversight system" that includes changing areas within the EPA that deal with science, personnel, international activities and, program integration and evaluation. Released May 23, the 76-page report outlines 25 steps that EPA, the government, the U.S. National Nanotechnology Initiative and industry should take to improve oversight. "This new report seeks to encourage … an intelligent oversight approach that empowers EPA and promotes investment and innovation in new nanotechnology products and processes," PEN Director David Rejeski says...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.